AustralieFrV1, Main, Exploration, bibRecord, 005929

Selection of chronic hepatitis B therapy with high barrier to resistance

Identifieur interne : 005929 ( Main/Exploration ); précédent : 005928; suivant : 005930

Selection of chronic hepatitis B therapy with high barrier to resistance

Auteurs : Robert Gish [États-Unis] ; Ji-Dong Jia [République populaire de Chine] ; Stephen Locarnini [Australie] ; Fabien Zoulim [France]

Source :

Lancet. Infectious diseases : (print) [ 1473-3099 ] ; 2012.

RBID : Pascal:12-0183144

Descripteurs français

Pascal (Inist)
- Hépatite virale B, Traitement, Résistance.

English descriptors

KwdEn :
- Resistance, Treatment, Viral hepatitis B.

Abstract

Antiviral drug resistance is a crucial factor that frequently determines the success of long-term therapy for chronic hepatitis B. The development of resistance to nucleos(t)ide analogues has been associated with exacerbations in liver disease and increased risk of emergence of multidrug resistance. The selection of a potent nucleos(t)ide analogue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achieving long-term treatment goals and should be used wherever possible. The barrier to resistance of a given nucleos(t)ide analogue is influenced by genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitness, mechanism of action, and cross-resistance. In countries with limited health-care resources, the selection of a therapy with a high barrier to resistance is not always possible and alternative strategies for preventing resistance might be needed, although limited data are available to support these strategies.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001466
to stream PascalFrancis, to step Curation: 004A46
to stream PascalFrancis, to step Checkpoint: 000D81
to stream Main, to step Merge: 005C16
to stream Main, to step Curation: 005929

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Selection of chronic hepatitis B therapy with high barrier to resistance</title>
<author><name sortKey="Gish, Robert" sort="Gish, Robert" uniqKey="Gish R" first="Robert" last="Gish">Robert Gish</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Hepatobiliary Disease and Abdominal Transplantation, UC San Diego Health System</s1>
<s2>San Diego, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>San Diego, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jia, Ji Dong" sort="Jia, Ji Dong" uniqKey="Jia J" first="Ji-Dong" last="Jia">Ji-Dong Jia</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Liver Research Center, Beijing Friendship Hospital, Capital Medical University</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Victorian Infectious Diseases Reference Laboratory, North Melbourne</s1>
<s2>VIC</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM, U1052, Cancer Research Center of Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University of Lyon, Institut Universitaire de France</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospices Civils de Lyon, Hepatology Department</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0183144</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0183144 INIST</idno>
<idno type="RBID">Pascal:12-0183144</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001466</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004A46</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D81</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D81</idno>
<idno type="wicri:doubleKey">1473-3099:2012:Gish R:selection:of:chronic</idno>
<idno type="wicri:Area/Main/Merge">005C16</idno>
<idno type="wicri:Area/Main/Curation">005929</idno>
<idno type="wicri:Area/Main/Exploration">005929</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Selection of chronic hepatitis B therapy with high barrier to resistance</title>
<author><name sortKey="Gish, Robert" sort="Gish, Robert" uniqKey="Gish R" first="Robert" last="Gish">Robert Gish</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Center for Hepatobiliary Disease and Abdominal Transplantation, UC San Diego Health System</s1>
<s2>San Diego, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>San Diego, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jia, Ji Dong" sort="Jia, Ji Dong" uniqKey="Jia J" first="Ji-Dong" last="Jia">Ji-Dong Jia</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Liver Research Center, Beijing Friendship Hospital, Capital Medical University</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Victorian Infectious Diseases Reference Laboratory, North Melbourne</s1>
<s2>VIC</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM, U1052, Cancer Research Center of Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>University of Lyon, Institut Universitaire de France</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospices Civils de Lyon, Hepatology Department</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet. Infectious diseases : (print)</title>
<title level="j" type="abbreviated">Lancet. Infect.  dis. : (print)</title>
<idno type="ISSN">1473-3099</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Resistance</term>
<term>Treatment</term>
<term>Viral hepatitis B</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hépatite virale B</term>
<term>Traitement</term>
<term>Résistance</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Antiviral drug resistance is a crucial factor that frequently determines the success of long-term therapy for chronic hepatitis B. The development of resistance to nucleos(t)ide analogues has been associated with exacerbations in liver disease and increased risk of emergence of multidrug resistance. The selection of a potent nucleos(t)ide analogue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achieving long-term treatment goals and should be used wherever possible. The barrier to resistance of a given nucleos(t)ide analogue is influenced by genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitness, mechanism of action, and cross-resistance. In countries with limited health-care resources, the selection of a therapy with a high barrier to resistance is not always possible and alternative strategies for preventing resistance might be needed, although limited data are available to support these strategies.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Lyon</li>
<li>Pékin</li>
</settlement>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Gish, Robert" sort="Gish, Robert" uniqKey="Gish R" first="Robert" last="Gish">Robert Gish</name>
</noRegion>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Jia, Ji Dong" sort="Jia, Ji Dong" uniqKey="Jia J" first="Ji-Dong" last="Jia">Ji-Dong Jia</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name>
</noRegion>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
</region>
<name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
<name sortKey="Zoulim, Fabien" sort="Zoulim, Fabien" uniqKey="Zoulim F" first="Fabien" last="Zoulim">Fabien Zoulim</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005929 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005929 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0183144
   |texte=   Selection of chronic hepatitis B therapy with high barrier to resistance
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Selection of chronic hepatitis B therapy with high barrier to resistance

Selection of chronic hepatitis B therapy with high barrier to resistance

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri